An Open Label, Single Arm, Multicenter Phase II Study of BKM120 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2017
At a glance
- Drugs Buparlisib (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 05 Apr 2017 Status changed from recruiting to completed, based on the results presented at the 108th Annual Meeting of the American Association for Cancer Research.
- 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research
- 02 Jun 2015 Interim results of buparlisib monotherapy in 37 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.